内容紹介
Study of the Response Rate and Neutrophil Lymphocyte Ratio in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Summary
The neutrophil lymphocyte ratio(NLR)is associated with the outcomes of some cancer patients such as those with digestive cancer. Herein, we examined the relationship between the response rate following neoadjuvant chemotherapy and NLR in breast cancer patients. We recruited 19 primary breast cancer patients who were administered neoadjuvant chemotherapy. We evaluated the effects of this treatment and classified the patients into responder(CR and PR)and non-responder(SD and PD)groups. We measured the value of NLR before or at the start of nab-PTX treatment, and 7 days after nab-PTX(1-1)and nab-PTX(4-3)treatment. The average age was 58.6 years. The responder and non-responder groups comprised 14 and 5 cases, respectively. The average values of NLR before or at the start of the nab-PTX phase were 4.33 and 5.05 in the responder and non-responder groups, respectively. The average NLR values 7 days after nab-PTX(1-1)were 6.72 and 5.60 in the responder and non-responder groups, respectively. The NLR values 7 days after nab-PTX(4-3)were 2.40 and 2.65 for the responder and non-responder groups, respectively. There were no significant differences between the responder and non-responder groups for each treatment phase.
要旨
好中球・リンパ球比(neutrophil lymphocyte ratio: NLR)は,複数の癌腫において予後と相関することが報告されている。われわれは乳癌における術前化学療法の奏効率とNLRの関連性を検討し,乳癌化学療法中にNLRを測定することの意義を検討した。術前化学療法を施行した原発性乳癌19例を対象とした。EC×4→nab-PTX×4を各4サイクル施行後,標的病変に対し効果判定を行い,奏効群(CR+PR),非奏効群(SD+PD)の2群に分類した。これらについてnab-PTX投与前,nab-PTX(1-1)投与後7日目,nab-PTX(4-3)投与後7日目における,それぞれのphaseにおけるNLRについて測定した。奏効群は14例,非奏効群は5例であった。NLR値はnab-PTX投与前,nab-PTX(1-1)7日目,nab-PTX(4-3)7日目のいずれのphaseにおいても奏効群と非奏効群間に差を認めなかった。
目次
Summary
The neutrophil lymphocyte ratio(NLR)is associated with the outcomes of some cancer patients such as those with digestive cancer. Herein, we examined the relationship between the response rate following neoadjuvant chemotherapy and NLR in breast cancer patients. We recruited 19 primary breast cancer patients who were administered neoadjuvant chemotherapy. We evaluated the effects of this treatment and classified the patients into responder(CR and PR)and non-responder(SD and PD)groups. We measured the value of NLR before or at the start of nab-PTX treatment, and 7 days after nab-PTX(1-1)and nab-PTX(4-3)treatment. The average age was 58.6 years. The responder and non-responder groups comprised 14 and 5 cases, respectively. The average values of NLR before or at the start of the nab-PTX phase were 4.33 and 5.05 in the responder and non-responder groups, respectively. The average NLR values 7 days after nab-PTX(1-1)were 6.72 and 5.60 in the responder and non-responder groups, respectively. The NLR values 7 days after nab-PTX(4-3)were 2.40 and 2.65 for the responder and non-responder groups, respectively. There were no significant differences between the responder and non-responder groups for each treatment phase.
要旨
好中球・リンパ球比(neutrophil lymphocyte ratio: NLR)は,複数の癌腫において予後と相関することが報告されている。われわれは乳癌における術前化学療法の奏効率とNLRの関連性を検討し,乳癌化学療法中にNLRを測定することの意義を検討した。術前化学療法を施行した原発性乳癌19例を対象とした。EC×4→nab-PTX×4を各4サイクル施行後,標的病変に対し効果判定を行い,奏効群(CR+PR),非奏効群(SD+PD)の2群に分類した。これらについてnab-PTX投与前,nab-PTX(1-1)投与後7日目,nab-PTX(4-3)投与後7日目における,それぞれのphaseにおけるNLRについて測定した。奏効群は14例,非奏効群は5例であった。NLR値はnab-PTX投与前,nab-PTX(1-1)7日目,nab-PTX(4-3)7日目のいずれのphaseにおいても奏効群と非奏効群間に差を認めなかった。